All In Biotech

Drug Trial Radar · NCT01054820

Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

Multicenter, Open-Label Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

Last checked: Nov 20, 2026Latest source record: Aug 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

123

Actual

Start

Jan 2010

Primary completion

Mar 2010

Study completion Mar 2010

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies.

Conditions

  • Acute Back Strain

Interventions

  • FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%Drug

    One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline to End of Treatment (EOT) in Response to Modified Brief Pain Inventory (mBPI) Question 5: Average Pain Over the Last 24 HoursTime frame: Baseline, End of Treatment (last visit up to Day 15)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.